Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer

BACKGROUND: The combination of capecitabine and gemcitabine at Fixed Dose Rate (FDR) has been demonstrated to be well tolerated, with apparent efficacy in patients with advanced cancers. FDR gemcitabine infusion leads to enhanced intracellular accumulation of drug and possible augmented clinical eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Santini, Daniele, Vincenzi, Bruno, Schiavon, Gaia, La Cesa, Annalisa, Gasparro, Simona, Vincenzi, Angelo, Tonini, Giuseppe
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1402306/
https://www.ncbi.nlm.nih.gov/pubmed/16504126
http://dx.doi.org/10.1186/1471-2407-6-42

Ejemplares similares

Ejemplares similares